Lisa Skeete Tatum
STRYKERAbout Lisa Skeete Tatum
Independent director since 2020; age 57. Founder and CEO of Landit, Inc.; prior venture investor and operating executive. Currently serves on Stryker’s Audit Committee; the Board has determined she is independent under NYSE standards. Five years of service at SYK as of the 2025 meeting slate.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Landit, Inc. | Founder & Chief Executive Officer | 2014–present | Technology-enabled career platform founder/executive |
| Angel/Fund Investor | Investor | 2010–2014 | Venture investing experience |
| Cardinal Partners | General Partner | 1998–2009 | Healthcare venture capital leadership |
| STI, Inc. | Founder | 1995–1998 | Early-stage operating leadership |
| Procter & Gamble | Various global/functional roles | 1989–1994 | Brand/operations foundation |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Union Square Hospitality Group | Board Member | Not disclosed | Private hospitality company |
| USHG Acquisition Corporation | Director | 2021–2022 | SPAC; prior public company directorship |
| Cornell University | Trustee Emeritus | Not disclosed | Non-profit governance |
Board Governance
- Committee assignments: Audit Committee member; the Audit Committee met nine times in 2024; chair is Andrew K. Silvernail; committee includes Ruggeri, Skeete Tatum, Suri. The Board designates Ruggeri and Silvernail as “audit committee financial experts.”
- Independence: Board determined all directors other than the CEO are independent; Skeete Tatum marked independent in the nominee table.
- Attendance: Board held seven meetings in 2024; each director attended at least 75% of Board and committee meetings on which they served.
- Board leadership and executive sessions: Combined Chair/CEO structure with a robust Lead Independent Director role (held by Sherilyn S. McCoy); independent directors hold regular executive sessions at least annually.
Fixed Compensation
| Component | Amount | Detail |
|---|---|---|
| Annual cash retainer | $126,432 | Fees earned in 2024 (annualized board fee set at $130,000 from May 2024) |
| Committee chair fees (context) | $25,000 (Audit Chair), $20,000 (other Chairs) | Applies to chairs; Skeete Tatum is not a chair |
| Lead Independent Director premium (context) | $40,000 | Applies to LID; Skeete Tatum is not LID |
| 2025 fee levels | Unchanged vs 2024 | Board confirmed 2025 annual non-employee director fees remain the same |
Performance Compensation
- Directors receive annual time-vested restricted stock units; no performance metrics tied to director equity (vesting generally one year, subject to plan design).
| Grant Date | Instrument | Shares Granted | Grant-Date Fair Value | Vesting/Settlement |
|---|---|---|---|---|
| May 9, 2024 | RSUs | 653 | $214,001 | Vest May 2025; optional deferral by director until departure/future date |
Other Directorships & Interlocks
| Company/Entity | Public/Private | Possible Interlock/Conflict |
|---|---|---|
| USHG Acquisition Corporation | Public (SPAC, prior) | No Stryker-related transaction disclosed |
| Union Square Hospitality Group | Private | No Stryker-related transaction disclosed |
| Cornell University | Non-profit | Not applicable |
Expertise & Qualifications
- Career founder/CEO in technology-enabled human capital; prior venture GP in healthcare; early P&G operating roles. Emphasis on innovation, human capital, and entrepreneurship reflected in her profile and SYK’s skills matrix framework.
Equity Ownership
| Item | Value | Notes |
|---|---|---|
| Shares owned directly | 2,239 | As of Feb 28, 2025 |
| RSUs outstanding (incl. deferred) | 1,644 | As of Dec 31, 2024 (director-level RSUs; some deferred) |
| Vested RSUs deferred (delivery) | 991 | Director-elected deferral until departure |
| Options outstanding | 0 | No director options outstanding for Skeete Tatum |
| Ownership % of outstanding | <1% | Aggregate disclosure; director-level ownership <1% |
| Stock ownership guideline | $600,000 within 5 years | Non-employee directors; all directors at/above or projected to be by target date as of 12/31/2024 |
| Hedging/pledging policy | Prohibited | Hedging and pledging generally prohibited under Insider Trading Guidelines |
Governance Assessment
- Strengths: Independent Audit Committee member with consistent meeting cadence; Board-wide attendance threshold met; strong director stock ownership guidelines and anti-hedging/pledging policy; say-on-pay support at ~91% signals investor alignment.
- Compensation structure: Balanced mix of cash retainer and annual RSU grant; RSUs time-vest over one year with optional deferral; fee levels remain stable for 2025.
- Risk considerations: Not designated as an “audit committee financial expert” (committee retains two named financial experts); no related-party transactions disclosed for Skeete Tatum.
- Change-in-control and clawback: Equity plans allow vesting acceleration and cash-out under certain CIC events; company-wide recoupment and mandatory clawback policies in place.
RED FLAGS: None disclosed specific to Skeete Tatum (no related-party transactions, pledging, or attendance issues reported).